RETRACTED ARTICLE:CIP2A mediates prostate cancer progression via the c-Myc signaling pathway

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4777-4783

  Guo, Zexiong ^a   Liu, Dehao ^a   Su, Zexuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

Cancerous inhibitor of protein phosphatase 2A; Invasion; Proliferation; Prostate cancer; Small interfering RNA; Targeted therapy

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AUTOANTIGEN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGED; ANIMAL; BIOSYNTHESIS; CELL MOTION; DISEASE COURSE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

AGED; ANIMALS; AUTOANTIGENS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938973460     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3129-4     Document Type: TB

References (15)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.
2. Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–53.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59(1):61–71.
4. Saad F, Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol. 2012;8(3):321–31.
5. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol. 2009;21:260–5.
6. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.
7. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.
8. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793–805.
9. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092–100.
10. Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl. 2013;15(1):110–5.
11. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.
12. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, et al. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One. 2013;8(10):e75292.
13. Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer. 2011;105(7):989–95.
14. Ren J, Li W, Yan L, Jiao W, Tian S, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients survival. Br J Cancer. 2011;105(12):1905–11.
15. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, et al. A signaling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18.